title: Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy.
abstract: Anthracyclines are a class of drugs, including doxorubicin, epirubicin and idarubicin, used in cancer chemotherapy which are derived from Streptomyces bacterium Streptomyces peucetius var. caesius. Traditionally, substantial pieces of evidence have demonstrated that anthracyclines could harness the host immune system to prevent cancer progression. But nowadays, researches also implied that anthracyclines could sensitize tumor cells to immune cell driven cytotoxicity, like dendritic cells and CD8+ T cell. The ability of anthracyclines in tumor immune cycle, including trigger direct tumor cell death, enhance immune effector cell activation and eliminate immunosuppressive myeloid-derived suppressor cells (MDSCs), explained its capacity to relieve tumor induced immunosuppression and restore anticancer immune responses. And current pre-clinical and clinical trials implied that combination therapies using anthracyclines with immunotherapy have further enhanced the clinical benefit. Here, we discuss how the increased understanding of the immune-driven effects of anthracyclines prompts the design of relevant cancer chemoimmunotherapy strategies.
authors.affiliation: Department of Gynecology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Zhang
authors.forename: Xiuyan
authors.initials: X
authors.lastname: Yu
authors.affiliation: Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
authors.forename: Xiuyang
authors.initials: X
authors.lastname: Yu
authors.affiliation: Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
authors.forename: Pin
authors.initials: P
authors.lastname: Wu
authors.affiliation: Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China. Electronic address: drhuangjian@zju.edu.cn.
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
mesh_terms: D018943:Anthracyclines / Q000276:immunology* / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D004317:Doxorubicin / Q000494:pharmacology*; D006801:Humans; D056747:Immunomodulation; D007167:Immunotherapy; D059016:Tumor Microenvironment
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin
keywords: Anthracyclines; Anticancer immunity; Chemoimmunotherapy; Doxorubicin; Immunomodulation